Companies Sana Biotechnology, Inc.
Sana Biotechnology (SANA): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Sana Biotechnology, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $2,671,662FY2023
- $8,788,580FY2024
- $2,903,010FY2025
CEO total pay was $2,903,010 in fiscal 2025, down from $8,788,580 in fiscal 2024.
FY2025: salary $696,140 · bonus $0 · stock awards $425,001 · option awards $1,327,500
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Steven Harr | $696,140 | $0 | $425,001 | $1,327,500 | $450,369 | $0 | $4,000 | $2,903,010 |
| President, Chief Executive Officer, and Director | ||||||||
| Bernard Cassidy | 404,034 | 0 | 135,999 | 424,800 | 0 | 0 | 51,280 | 1,016,113 |
| Former Executive Vice President, General Counsel, and Corporate Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Steven Harr | $2,903,010 | $8,788,580 | $2,671,662 | ↓ −5,885,570 |
| Bernard Cassidy | 1,016,113 | 2,345,597 | 987,382 | ↓ −1,329,484 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
We have a pay-for-performance focused executive compensation philosophy. We believe that compensation should be designed to drive company performance to increase stockholder value. We seek to achieve this by using different elements of compensation and a market-based approach to attract, retain, and motivate a high-performing team of executive officers, and by aligning a majority of the compensation of each of our executives with the company's short- and long-term performance.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon plc (Human Capital Solutions practice) |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Steven Harr | OPTION | — | — | — | — | — | $1,327,500 |
| Bernard Cassidy | OPTION | — | — | — | — | — | 424,800 |
| Steven Harr | RSU | — | — | — | — | — | 425,001 |
| Bernard Cassidy | RSU | — | — | — | — | — | 135,999 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Steven Harr | $425,001 | $0 | $1,327,500 | 0.0% |
| Bernard Cassidy | 135,999 | 0 | 424,800 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Bernard Cassidy | RSU | 33,126 | — | $134,823 |
| Bernard Cassidy | Option | 43,750 | 3.76 | — |
| Steven Harr | Option | 47,500 | 5.7 | — |
| Bernard Cassidy | RSU | 53,333 | — | 217,065 |
| Bernard Cassidy | Option | 111,797 | 9.58 | — |
| Steven Harr | RSU | 150,000 | — | 610,500 |
| Bernard Cassidy | Option | 150,000 | 7.13 | — |
| Steven Harr | RSU | 166,667 | — | 678,335 |
| Steven Harr | Option | 203,125 | 3.76 | — |
| Bernard Cassidy | Option | 240,000 | 2.55 | — |
| Steven Harr | Option | 506,250 | 9.58 | — |
| Steven Harr | Option | 750,000 | 2.55 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Robert L. RosielloIndependent · Audit · Compensation and Talent | $30,119 | $0 | $200,577 | $0 | $0 | $230,696 |
| Hans E. BishopIndependent · Board Chair · Audit · Compensation and Talent (Chair) | 97,727 | 0 | 122,787 | 0 | — | 220,515 |
| Michelle Seitz, CFAIndependent · Audit (Chair) | 60,000 | 0 | 122,787 | 0 | 0 | 182,787 |
| Alise S. Reicin, M.DIndependent · Compensation and Talent | 47,500 | 0 | 122,787 | 0 | 0 | 170,287 |
| Joshua H. Bilenker, M.DIndependent · Nominating and Corporate Governance (Chair) | 46,729 | 0 | 122,787 | 0 | — | 169,517 |
| Patrick Y. Yang, Ph.DIndependent · Nominating and Corporate Governance | 45,000 | 0 | 122,787 | 0 | 0 | 167,787 |
| Robert NelsenIndependent | 40,000 | 0 | 122,787 | 0 | 0 | 162,787 |
| Richard Mulligan, Ph.DNot independent | 40,000 | 0 | 122,787 | 0 | 0 | 162,787 |
| Mary Agnes (Maggie) WilderotterIndependent · Audit · Nominating and Corporate Governance (Chair) · Departed during FY | 39,783 | 0 | 122,787 | 0 | 0 | 162,570 |
| Douglas Cole, M.DIndependent · Compensation and Talent · Departed during FY | 20,488 | 0 | 0 | 0 | 0 | 20,488 |
| Steven D. Harr, M.DEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $425,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $467,346 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $467,346 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Sana Biotechnology as a peer
Companies that benchmark against SANA
8 companies name SANA as a compensation peer
The list of companies that name SANA as a peer is temporarily unavailable — recheck shortly.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Sana Biotechnology, Inc. | 2025 | Steven Harr | $696,140 | $425,001 | $1,327,500 | $450,369 | $2,903,010 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Joshua H. Bilenker | Director | 2026-06-04 | A | 90,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Hans E. Bishop | Director | 2026-06-04 | A | 90,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michelle Seitz | Director | 2026-06-04 | A | 90,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert L. Rosiello | Director | 2026-06-04 | A | 90,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Mulligan | Director | 2026-06-04 | A | 90,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Nelsen | Director | 2026-06-04 | A | 90,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Alise Reicin | Director | 2026-06-04 | A | 90,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick Y. Yang | Director | 2026-06-04 | A | 90,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hans E. Bishop | Director | 2026-07-06 | A | 6,297 | 0 | 0 | Common | Form 4 ↗ |
| Dhavalkumar Dhirajlal Patel | EVP, Chief Scientific Officer | 2026-08-26 | D | 125,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dhavalkumar Dhirajlal Patel | EVP, Chief Scientific Officer | 2026-08-26 | A | 125,000 | 0 | 0 | Common | Form 4 ↗ |
| Dhavalkumar Dhirajlal Patel | EVP, Chief Scientific Officer | 2026-08-27 | D | 41,158 | 4 | 169,159 | Common | Form 4 ↗ |
| Hans E. Bishop | Director | 2026-10-05 | A | 8,680 | 0 | 0 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (35 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Steven Harr. DEF 14A, filed 2026-04-24. Section “Summary Compensation Table” · page 25. As printed: 2,903,010. View filing ↗
- Section 01, Bernard Cassidy. DEF 14A, filed 2026-04-24. Section “Summary Compensation Table” · page 25. As printed: 1,016,113. View filing ↗
- Section 03, Steven Harr OPTION. DEF 14A, filed 2026-04-24. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Bernard Cassidy OPTION. DEF 14A, filed 2026-04-24. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Steven Harr RSU. DEF 14A, filed 2026-04-24. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Bernard Cassidy RSU. DEF 14A, filed 2026-04-24. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-03-03. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Robert L. Rosiello. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 230,696. View filing ↗
- Section 08, Hans E. Bishop. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 220,515. View filing ↗
- Section 08, Michelle Seitz, CFA. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 182,787. View filing ↗
- Section 08, Alise S. Reicin, M.D. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 170,287. View filing ↗
- Section 08, Joshua H. Bilenker, M.D. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 169,517. View filing ↗
- Section 08, Patrick Y. Yang, Ph.D. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 167,787. View filing ↗
- Section 08, Robert Nelsen. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 162,787. View filing ↗
- Section 08, Richard Mulligan, Ph.D. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 162,787. View filing ↗
- Section 08, Mary Agnes (Maggie) Wilderotter. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 162,570. View filing ↗
- Section 08, Douglas Cole, M.D. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 20,488. View filing ↗
- Section 08, Steven D. Harr, M.D. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Joshua H. Bilenker 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hans E. Bishop 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michelle Seitz 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert L. Rosiello 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Mulligan 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Nelsen 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alise Reicin 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick Y. Yang 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hans E. Bishop 2026-07-06. Form 4, filed 2026-07-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dhavalkumar Dhirajlal Patel 2026-08-26. Form 4, filed 2026-08-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dhavalkumar Dhirajlal Patel 2026-08-26. Form 4, filed 2026-08-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dhavalkumar Dhirajlal Patel 2026-08-27. Form 4, filed 2026-08-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hans E. Bishop 2026-10-05. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 467,346 + equity 0 + all other 0 = 467,346, summed across the director compensation table rows.
- Sana Biotechnology, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Sana Biotechnology, Inc.'s own proxy. As printed: 2,903,010. View filing ↗